Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models

Katherine E. LewisOncology Discovery Research, Bristol-Myers Squibb, Seattle, WA

Mark J. SelbyOncology Discovery Research, Bristol-Myers Squibb, Redwood City, CA

Gregg MastersOncology Translational Research, Bristol-Myers Squibb, Princeton, NJ

Jose ValleOncology Discovery Research, Bristol-Myers Squibb, Redwood City, CA

Gennaro DitoOncology Translational Research, Bristol-Myers Squibb, Princeton, NJ

Wendy R. CurtisOncology Discovery Research, Bristol-Myers Squibb, Seattle, WA

Richard GarciaOncology Discovery Research, Bristol-Myers Squibb, Seattle, WA

Kathy A. MinkOncology Discovery Research, Bristol-Myers Squibb, Seattle, WA

Kimberly S. WaggieOncology Discovery Research, Bristol-Myers Squibb, Seattle, WA

Matthew S. HoldrenDrug Safety Evaluation, Bristol-Myers Squibb, Mt. Vernon, IN

Joseph F. GrossoEarly Clinical Development, Bristol-Myers Squibb, Princeton, NJ

Alan J. KormanOncology Discovery Research, Bristol-Myers Squibb, Redwood City, CA

Maria Jure-KunkelOncology Translational Research, Bristol-Myers Squibb, Princeton, NJ

Stacey R. DillonOncology Discovery Research, Bristol-Myers Squibb, Seattle, WACorrespondence[email protected]

Your download is now in progress and you may close this window